Recent evidence suggests that the the chemokine fractalkine (CX3CL1) /CX3CL1 receptor (CX3CR1) axis abrogates the deleterious effects on microglia proliferation in PD by upregulating Nrf2 expression. This evidence concerns the gene CX3CL1 and Parkinson disease.